OBESE-HFpEF: Towards Preventing Obesity Related HFpEF, Netherlands
Summary
The Netherlands Heart Foundation has registered an observational study (NCT07539766) in ClinicalTrials.gov examining how obesity contributes to heart failure with preserved ejection fraction (HFpEF). The study will enroll approximately 250 participants with obesity in South Limburg, using echocardiography and blood/tissue tests to identify early HFpEF markers, with follow-up at 1 and 2 years. Results may inform future treatment strategies for patients with obesity-related HFpEF.
What changed
This entry registers a new observational clinical study (NCT07539766) titled 'OBESE-HFpEF' on ClinicalTrials.gov, the NIH-maintained clinical research registry. The study is sponsored by a Dutch institution and will investigate the relationship between obesity and HFpEF using cardiac ultrasound and biomarker analysis.
Healthcare researchers and clinical trial sponsors conducting obesity-related cardiovascular research should be aware of this study as it may inform future treatment approaches for HFpEF. The study's focus on early detection and weight-loss intervention outcomes could influence research priorities in this patient population.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
OBESE-HFpEF: Towards Preventing Obesity Related HFpEF
Observational NCT07539766 Kind: OBSERVATIONAL Apr 20, 2026
Abstract
Obesity, severe overweight, is a growing problem worldwide and increases the risk of heart failure, especially a type called heart failure with preserved ejection fraction (HFpEF).
In HFpEF, the heart becomes stiffer. This makes it harder for the heart to fill with blood, which can lead to shortness of breath during physical activity.
In the Netherlands, 15% of the population has obesity. In South Limburg, this is even higher at 19%. Among people with HFpEF, obesity is much more common: about 50% of these patients have obesity.
Life expectancy in people with HFpEF is poor, and current treatment mainly focuses on reducing symptoms. Early recognition and treatment of risk factors, such as obesity, are therefore very important.
This study includes about 250 people with obesity. Using a heart ultrasound and tests of blood and fat tissue, we will look for early signs of HFpEF and study the effects of weight loss. The measurements will be repeated after 1 and 2 years.
The goal of this study is to better understand how obesity contributes to HFpEF and how weight loss affects the heart. This research may help improve future treatments for patients with HFpEF.
Conditions: Heart Failure and Preserved Ejection Fraction, Obesity (Disorder), Heart Failure
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.